UCB Patents – Key Insights and Stats

UCB has a total of 11185 patents globally, out of which 9029 have been granted. Of these 11185 patents, more than 52% patents are active. China is where UCB has filed the maximum number of patents, followed by Japan and Korea (South). Parallelly, United States of America seems to be the main focused R&D centre and also Belgium is the origin country of UCB.

UCB was founded in the year 1928. The Company operates as a biopharmaceutical company. The Company specializes in the treatment of central nervous system disorders and inflammatory diseases. As of April 2023, the market cap of UCB is $18.17 Billion.

Do read about some of the most popular patents of UCB which have been covered by us in this article and also you can find UCB patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over UCB patent portfolio.

How many patents does the founder and the CEO of UCB have?

The founder Emmanuel Janssen has 0 patent and CEO Jean-Christophe Tellier has 0 patent.

How many patents does UCB have?

UCB has a total of 11185 patents globally. These patents belong to 3244 unique patent families. Out of 11185 patents, 5869 patents are active.

How Many Patents did UCB File Every Year?

UCB Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantUCB Applications FiledUCB Patents Granted
20233105
2022176684
2021291772
2020483739
2019589971
2018749771
2017764702
2016893601
2015850496
2014685493
2013742412
2012504397
2011513473

Which UCB Drug Patents are Expiring in the Next 10 Years?

The patent no. US10452815B2 which is expiring in Jun, 2038, describing to manage the distribution of epilepsy medication by using a central controller with a database of patient records. The controller authorizes the first prescription based on genetic test results and schedules additional tests before approving subsequent prescriptions.

Given below is the list of few drugs patented by UCB accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
FinteplaUS10452815B2Control System For Control Of Dist…Jun, 2038
NeuproUS8246980B2Transdermal Delivery SystemNov, 2025
NayzilamUS8217033B2Methods And Compositions For…Jan, 2028
BriviactUS10729653B2Pharmaceutical Compositions Comp…Apr, 2030
KeppraUS8802142B2Pharmaceutical Compositions Comp…Dec, 2031

How many UCB patents are Alive/Dead?

UCB Patent Portfolio

 How Many Patents did UCB File in Different Countries?

UCB Worldwide Patent Filing

Countries in which UCB Filed Patents

CountryPatents
China1798
Japan1502
Korea (South)1035
United States Of America841
Europe595
United Kingdom358
Germany342
Canada322
Australia282
Spain269
Brazil243
India229
Israel179
Hong Kong (S.A.R.)178
Mexico176
Singapore144
Eurasia138
Denmark116
Poland115
Norway101
Indonesia95
Portugal94
Slovenia85
Malaysia84
Chile82
Taiwan79
Russia77
Croatia71
Hungary70
New Zealand65
Colombia64
Argentina63
Austria63
South Africa62
Malta59
Lithuania57
Cyprus54
Serbia52
Philippines43
Albania43
Italy41
Viet Nam33
Peru29
Turkey27
Uruguay24
Montenegro22
Ukraine20
Pakistan19
Morocco17
Africa16
Tunisia14
Luxembourg13
Netherlands12
Saudi Arabia9
Mongolia7
Paraguay7
Czech Republic6
San Marino6
Costa Rica6
Slovakia5
Bulgaria5
Gulf Cooperation Council5
Bolivia4
Former Yugoslav Republic of Macedonia4
Iceland4
Ecuador3
Georgia3
Uzbekistan3
Belgium3
Dominican Republic3
Egypt2
Estonia2
United Arab Emirates2
Kenya2
Romania2
Macao2
Guatemala2
Belarus1
Bangladesh1
Brunei1
Cuba1

Where are Research Centres of UCB Patents Located?

R&D Center of UCB

 10 Best UCB Patents

WO2009040562A1 is the most popular patent in the UCB portfolio. It has received 351 citations so far from companies like Glaxo Group Limited, MedImmune and Amgen.

Below is the list of 10 most cited patents of UCB:

Publication NumberCitation Count
WO2009040562A1351
US6583813B1331
WO2013186229A1313
WO2010035012A1309
WO2014009295A1274
WO2014009296A1241
WO2011086091A1213
US8993731B2212
WO2011110621A1199
US7592429B2173

How many inventions of other companies were rejected due to UCB patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to UCB invention. They couldn’t because UCB had protected those before them.

Examiners at the USPTO referred 117 UCB patents in 530 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the UCB patent portfolio are Amgen, Adamas Pharmaceuticals and Lts Lohmann Therapie Systeme.

List of the Companies whose Patents were rejected citing UCB –

CompanyNumber of Patent Applications that faced Rejection Citing UCB PatentsNumber of Rejections (102 & 103)
Amgen823
Adamas Pharmaceuticals69
Lts Lohmann Therapie Systeme620
West Pharmaceutical Services58
Shl Medical514
Sanofi-Aventis Deutschland518
Zogenix49
Quest Diagnostics Investments35
Individual34
Google312

Count of 102 and 103 Type Rejections based on UCB Patents

 Top UCB Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US8579866B212
US6583813B110
US7592429B29
US7812731B28
US10479824B28
US9230101B28
US8211462B26
US7863316B26
US8629246B26
US8945067B26
US10149818B25
US7419659B25
US20080274061A15
US20180211010A15
US7858122B25

What Percentage of UCB US Patent Applications were Granted?

UCB (Excluding its subsidiaries) has filed 293 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 185 have been granted leading to a grant rate of 65.37%.

Below are the key stats of UCB patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for UCB?

Law FirmTotal ApplicationsSuccess Rate
Wenderoth Lind & Ponack7837.18%
Mcdonnell Boehnen Hulbert & Berghoff5885.71%
Cozen O Connor1855.56%
Marshall Gerstein & Borun1593.33%
Morgan Lewis & Bockius944.44%
Medler Ferro Woodhouse & Mills883.33%
Saul Ewing Arnstein & Lehr850.00%
Finnegan Henderson Farabow666.67%
Cushman Darby & Cushman5100.00%
Ping Wang580.00%

What are UCB key innovation segments?

What Technologies are Covered by UCB?

The chart below distributes patents filed by UCB in different countries on the basis of the technology protected in patents. It also represents the markets where UCB thinks it’s important to protect particular technology inventions.

R&D Focus: How has UCB search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by UCB?

Related Articles

Weo Llc Patents – Insights & Stats (Updated 2024)

Weo Llc has a total of 47 patents globally, out of which 9 have been granted. Of these 47 patents, more than 87% patents are active. The United States of America is where Weo Llc has filed the maximum number of patents, followed by Brazil and Australia. Parallelly, France seems

Read More »

Fortephest Patents – Insights & Stats (Updated 2024)

Fortephest has a total of 23 patents globally. Of these 23 patents, more than 91% patents are active. Argentina is where Fortephest has filed the maximum number of patents, followed by New Zealand and Australia. Parallelly, The United States of America seems to be the main focused R&D center and

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.